Filing Details
- Accession Number:
- 0000899243-21-032196
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-09 17:17:27
- Reporting Period:
- 2021-08-05
- Accepted Time:
- 2021-08-09 17:17:27
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1787400 | Nkarta Inc. | NKTX | Pharmaceutical Preparations (2834) | 474515206 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1816676 | Kanya Rajangam | C/O Nkarta, Inc. 6000 Shoreline Court, Suite 102 South San Francisco CA 94080 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-08-05 | 10,000 | $0.41 | 10,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-08-05 | 10,000 | $37.28 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2021-08-05 | 10,000 | $0.00 | 10,000 | $0.41 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
44,054 | 2028-12-06 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date.
- This transaction was executed in multiple trades at prices ranging from $37.02 to $37.63, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- The options exercised were fully vested. Unvested options will vest and become exercisable ratably in monthly installments until fully vested on December 3, 2022.